A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials

Cancer

Volumn 115, Issue 11, 2009, Pages 2410-2419

  Lansdorp Vogelaar, Iris ^a   Van Ballegooijen, Marjolein ^a   Boer, Rob ^a   Zauber, Ann ^b   Habbema, J Dik F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal neoplasms; Occult blood; Sensitivity and specificity; Statistical models

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FECES ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSIMULATION MODEL; MULTICENTER STUDY; OCCULT BLOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; OCCULT BLOOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 66649091232     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24256     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-1477. (Pubitemid 26400242)
3. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and 7 biennial screening rounds. Gut. 2002;50:29-32. (Pubitemid 34028299)
4. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-437. (Pubitemid 29128279)
5. Moss SM, Hardcastle JD, Coleman DA, Robinson MH, Rodrigues VC. Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test. Int J Epidemiol. 1999;28:386-390. (Pubitemid 29276694)
6. Gyrd-Hansen D, Sogaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol. 1997;26:1172-1181. (Pubitemid 28010434)
7. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test. J Natl Cancer Inst. 1997;89:1440-1448. (Pubitemid 27419207)
8. Neddermeijer HG, Piersma N, Gerrit J, van Oortmarssen GJ, Habbema JDF, Dekker RB. Comparison of response surface methodology and the Nelder and Mead simplex method for optimization in microsimulation models. Rotterdam: Econometric Institute; 1999.
9. Wright MH. Direct search methods: once scorned, now respectable. In: Griffiths DF, Watson GA, eds. Numerical analysis 1995 (proceedings of the 1995 Dundee Biennial Conference in Numerical Analysis). United Kingdom: Addison Wesley Longman, Harlow; 1996:191-208.
10. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365-1371.
11. Loeve F, Boer R, van Ballegooijen M, van Oortmarssen G, Habbema JDF. Final report MISCAN-COLON microsimulation model for colorectal cancer. Rotterdam: Department of Public Health, Erasmus University; 1998.
12. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JDF. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999;32:13-33. (Pubitemid 29102594)
13. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst. 2000;92:557-563. (Pubitemid 30212317)
14. Vogelaar I, van Ballegooijen M, Zauber AG, et al. Model profiler of the MISCAN-Colon microsimulation model for colorectal cancer. Department of Public Health, Erasmus MC, 2004. Available at: http://cisnet.cancer.gov/profiles Accessed September 9, 2008.
15. Morson B. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974;67:451-457.
16. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36:2251-2270.
17. Kyle SM, Isbister WH, Yeong ML. Presentation, duration of symptoms and staging of colorectal carcinoma. Aust N Z J Surg. 1991;61:137-140.
18. Lanier AP, Wychulis AR, Dockerty MB, Elveback LR, Beahrs OH, Kurland LT. Colorectal cancer in Rochester, Minnesota 1940-1969. Cancer. 1973;31:606-615.
19. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol. 1999;94:3039-3045. (Pubitemid 29482779)
20. Speights VO, Johnson MW, Stoltenberg PH, Rappaport ES, Helbert B, Riggs M. Colorectal cancer: current trends in initial clinical manifestations. South Med J. 1991;84:575-578.
21. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155-159. (Pubitemid 26017953)
22. Collins JF, Lieberman DA, Durbin TE, Weiss DG; Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81-85.
23. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704-2714. (Pubitemid 39665324)
24. Lieberman DA, Weiss DG; Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555-560.
25. Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol. 1994;3:27-36. (Pubitemid 24171938)
26. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg. 1994;81:448-451. (Pubitemid 24124835)
27. Castiglione G, Biagini M, Barchielli A, et al. Effect of rehydration on guaiac-based faecal occult blood testing in colorectal cancer screening. Br J Cancer. 1993;67:1142-1144. (Pubitemid 23147519)
28. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer. 1988;62:645-651.
29. Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997;157:970-976.
30. Macrae FA, St John DJ. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology. 1982;82(pt 1):891-898.
31. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:96-104.